Androgen deprivation therapy in men with prostate cancer reduces risk of thyroid diseases: Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2022-04-18 03:30 GMT | Update On 2022-04-18 03:30 GMT

Taiwan: The use of androgen deprivation therapy (ADT) in men with metastatic prostate cancer (PCa) is tied to a reduced risk of thyroid disease development, says a recent study. The study was published in the Wiley journal Prostate.

Androgen hormones, such as testosterone are usually required by prostate cancer cells for their growth. Androgen deprivation therapy (ADT) reduces the levels of androgen hormones, with surgery or drug, to prevent the growth of prostate cancer cells. Androgen deprivation therapy also called androgen suppression therapy, is an antihormone therapy which is the major treatment for metastatic prostate cancer (PCa) but not much research has been done on the effects of ADT on thyroid diseases.

Against the above backgrdound, Jui-Ming Liu and colleagues conducted the population-based, nationwide cohort study with an objective to analyze the association between ADT and the development of thyroid diseases.

For this purpose, the researchers utilized the Taiwan National Health Insurance Research Database (NHIRD) with 17,192 PCa patients between 1997 and 2013. The association between ADT and the development of thyroid diseases was analyzed using Cox proportional hazards models and propensity score-matched analysis.

A total of 17,192 newly diagnosed men with PCa were selected from the NHIRD.

Based on the study, the researchers reported the following findings:

· There were 6200 ADT users and 6200 non-ADT users after 1:1 propensity score matching.

· There was a significantly decreased risk of thyroid diseases among ADT users compared with non-ADT users (adjusted hazard ratio (aHR): 0.79).

· Further analysis showed a significantly decreased risk of thyroid diseases with increasing ADT duration.

"Our findings showed that ADT use in men with PCa was associated with a decreased risk of thyroid disease development," the researchers concluded.

Reference:

Liu JM, Chen YT, Wu CT, Hsu WL, Hsu RJ. Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases. Prostate. 2022 May;82(7):809-815. doi: 10.1002/pros.24323. Epub 2022 Feb 28. PMID: 35226371.

Article Source : Prostate journal

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Androgen deprivation therapy in men with prostate cancer reduces risk of thyroid diseases: Study

Similar News

SOX2: a key player in prostate cancer progression and treatment resistance: Study

Steroidal MRAs Ineffective and Risky in Kidney Transplant Recipients: Study

Penile Implant Satisfaction Drops in Prostate Cancer Patients on Hormonal Treatment, reveals study

JnJ bags USFDA nod for bladder cancer treatment Inlexzo

Why male embryos grow faster: Study reveals genetic clues

Protein deficiency during pregnancy and lactation may compromise sperm viability in offspring: Study

Urinary NGAL Emerges as a Reliable Biomarker in Nephrotic Syndrome: Study Finds

Women With Metabolic Syndrome Face Higher Odds of Overactive Bladder: Study